Paul Christopher Williams - Mar 3, 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: Chief Operating Officer
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Paul Christopher Williams
Stock symbol: CTKB
Transactions as of: Mar 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/7/2023, 06:53 PM
Previous filing: Nov 2, 2022
Next filing: May 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTKB	Employee Stock option (right to buy)	Award	$0	+22.3K		$0.00	22.3K	Mar 3, 2023	Common Stock	22.3K	$10.61	Direct	F1
transaction	CTKB	Restricted Stock Units	Award	$0	+14.7K		$0.00	14.7K	Mar 3, 2023	Common Stock	14.7K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027.
F2	Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3	The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.